Cantor Fitzgerald Maintains Neutral on Merck & Co, Raises Price Target to $155
Benzinga Newsdesk 2 weeks ago
Analyst RatingsNewsPrice TargetHot
This page contains a summary, not the full article. Continue to benzinga.com to read the original report.
Cantor Fitzgerald analyst Carter Gould maintains Merck & Co (NYSE:MRK) with a Neutral and raises the price target from $145 to $155.
Cantor Fitzgerald analyst Carter Gould maintains Merck & Co (NYSE:MRK) with a Neutral and raises the price target from $145 to $155.
More on MRK
FDA & biotech Benzinga
Merck Reports Positive Survival Data For Investigational Therapy for Advanced Gastric CancerMerck's Phase 3 TroFuse-015 trial of sacituzumab tirumotecan met its primary overall survival endpoint in advanced gastroesophageal cancer.

Benzinga
Merck's Pivotal Phase 3 Trofuse-015 Trial Meets Primary Endpoint Of Overall Survival In Pretreated Gastroesophageal AdenocarcinomaSac-TMT is the first TROP2 ADC to improve OS compared to treatment of physician’s choice (TPC) in patients with advanced gastroesophageal adenocarcinoma who have received two or more prior lines of…
